Ever wonder how a small business can pivot when a global pandemic occurs? Josh Arant, co-founder MAKO Medical, discusses how they disrupted the status quo with passion and a heartfelt desire to give more to their clients. Then, how they rose to meet the needs of their community and country during a time of crisis.

Cell and gene therapies may well be some of the most important recent advancements in modern medicine. The way they work, however, is very complex and completely different from any pill that simply addresses symptoms. So, who are the pioneers in this field and what dares them to ask, “what if”?  In this episode of the Biotech Innovators podcast, learn from Ainslie Little, senior vice president of corporate strategy at BlueRock Therapeutics, and how her company’s cell & gene platform is breaking new ground in this important space.

Dr. Schiffman is a pediatric hematologist-oncologist and co-founder/CEO of PEEL Therapeutics headquartered in Salt Lake City, UT, USA and Haifa, Israel. It's a clinical-stage biotech company with a serendipitous origin story and a bright future. The company's name is the Hebrew word for elephant—an animal with amazing cancer-fighting genes that ignited the imaginations of Dr. Schiffman and his partners, sparking a new approach to fighting disease in humans starting with cancer and inflammatory diseases. PEEL's work is inspired by evolution and focuses on the science and the interconnectedness of all life on Earth. They aim to turn millions of years of evolution into the medicine humans need today.

We're living during a time of enormous technological breakthroughs and innovation is the key to shaping the world. However, when it comes to the biotech industry and biotechnological drug development,  science has to always be at the center of them.In this episode of the Biotech Innovators podcast, we welcome Samir Ounzain, the co-founder & CEO of Haya Therapeutics. They talk about Samir's path from watching Jurassic Park in a dark theater as a kid to studying the dark matter of the human genome in a lab – and eventually, to the founding of Haya Therapeutics.